Evidence map›Paper›PMID 40645528›Full record

ArticleJournal of affective disorders2025

Treatment resistant depression: Socio-demographic characteristics, comorbidity and treatment patterns from the All of Us Research Program.

Katherine L Forthman, Rayus Kuplicki, Wesley K Thompson, Charles B Nemeroff, Yajuan Si, Chun Chieh Fan, Martin P Paulus

Abstract read
In one paragraph

Article in Journal of affective disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Katherine L ForthmanLaureate Institute for Brain Research, Oxley College of Health and Natural Sciences, University of Tulsa, 6655 S Yale Ave, Tulsa, OK 74136-3326, United States of America.
Rayus KuplickiLaureate Institute for Brain Research, Oxley College of Health and Natural Sciences, University of Tulsa, 6655 S Yale Ave, Tulsa, OK 74136-3326, United States of America.
Wesley K ThompsonLaureate Institute for Brain Research, Oxley College of Health and Natural Sciences, University of Tulsa, 6655 S Yale Ave, Tulsa, OK 74136-3326, United States of America.
Charles B NemeroffDepartment of Psychiatry and Behavioral Sciences, Dell Medical School, The University of Texas at Austin, Austin, TX 78712-1873, United States of America.
Yajuan SiSurvey Research Center, Institute for Social Research, University of Michigan, ISR 4014, 426 Thompson St, Ann Arbor, MI 48104, United States of America.
Chun Chieh FanLaureate Institute for Brain Research, Oxley College of Health and Natural Sciences, University of Tulsa, 6655 S Yale Ave, Tulsa, OK 74136-3326, United States of America.
Martin P PaulusLaureate Institute for Brain Research, Oxley College of Health and Natural Sciences, University of Tulsa, 6655 S Yale Ave, Tulsa, OK 74136-3326, United States of America. Electronic address: mpaulus@laureateinstitute.org.

Funding

The Center for Neuroscience-based Mental Health Assessment and Prediction (NEUROMAP)P20GM121312 · NIGMS · LAUREATE INSTITUTE FOR BRAIN RESEARCH · PI Maëlle Camille Marie Gueguen · 2017 to 2026
$23.7M
15/21 ABCD-USA Consortium: Research Project Site at LIBRU01DA050989 · NIDA · LAUREATE INSTITUTE FOR BRAIN RESEARCH · PI ROBIN L AUPPERLE, MARTIN P. PAULUS · 2020 to 2026
$14.7M
Statistical adjustments of sample representation in community-level estimates of COVID-19 transmission and immunityU01MD017867 · NIMHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SI, YAJUAN · 2022 to 2025
$2.2M
NIDA NIH HHS U01 DA050989NIGMS NIH HHS P20 GM121312NIMHD NIH HHS U01 MD017867
6 · The paper itself

Abstract

objectiveThis study used the All of Us (AoU) cohort to investigate treatment-resistant depression (TRD) and its demographic associations, comorbidities and antidepressant treatment patterns.

methodsElectronic health records were used to classify major depressive disorder participants as treatment resistant. Logistic regressions determined socio-demographic and comorbidity differences between participants with TRD and treatment-responsive depression. Sankey diagrams visualized differences in treatment patterns.

results13.92 % of the depression population was characterized as TRD. The TRD population was 19.10 % of the medicated depression population. Compared to treatment-responsive depression individuals, those with TRD had lower education (Odds Ratio (OR) = 1.10 [1.03, 1.16]), were unemployed (OR = 1.35 [1.27, 1.43]) or in lower income brackets (OR < 35 k = 1.10 [1.03, 1.18]), and were more likely to be between ages 35-44 (OR = 1.15 [1.07, 1.24]). TRD relative to treatment-responsive depression individuals were more likely to have comorbidity with anxiety disorders (ORs ranging from 1.85 to 2.56 for various forms), Post-Traumatic Stress Disorder (OR = 2.10) and substance use disorders (ORs from 1.36 to 3.12). A Sankey diagram revealed heterogeneity in treatment among TRD and treatment-responsive depression.

conclusionThis study finds that TRD is especially prevalent among younger individuals, those with lower income, the unemployed, and individuals with comorbid anxiety or substance use disorders. This underscores the importance of integrating socio-demographic and clinical characteristics into targeted strategies aimed at identifying high-risk populations and guiding more effective treatment approaches.

Indexed as

Antidepressive AgentsDepressive Disorder, Treatment-ResistantCohort StudiesComorbidityFemaleHispanic or LatinoHumansMaleMiddle AgedPrevalenceRacial GroupsSex FactorsSocioeconomic FactorsUnited StatesAntidepressive AgentsAll of UsComorbidityDifficult-to-treat depressionTreatment patternsTreatment-resistant depression

Identifiers

PMID40645528
PMCPMC12285217

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.